237 results on '"Shah, Sanjiv"'
Search Results
2. Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Rationale, Design and Lead-in Phase Results of the REBALANCE-HF Trial
3. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy
4. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
5. Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study
6. Racial Differences of Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction
7. Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life
8. Missense Genetic Variation of ICAM1 and Incident Heart Failure
9. HFpEF in Japan: When an Epidemiological Transition Becomes an Epidemiological Opportunity
10. Multiple Prior Live Births Are Associated With Cardiac Remodeling and Heart Failure Risk in Women
11. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study
12. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
13. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
14. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study
15. Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF
16. Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction
17. Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction
18. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
19. Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction
20. Endovascular Ablation Of The Right Greater Splanchnic Nerve In Heart Failure With Preserved Ejection Fraction: Primary Results Of The REBALANCE-HF Randomized Trial
21. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study
22. Effects Of Semaglutide Across The Range Of Left Ventricular Ejection Fraction In Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Trial
23. Long-Term Effects Of Atrial Shunt Device On Cardiac Structure And Function In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: Results From The REDUCE LAP-HF II Randomized Clinical Trial
24. With Great Data Come Great Responsibilities: The Cardiac Amyloidosis Registry Study
25. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy
26. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
27. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization
28. Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans
29. Pre-Heart Failure Risk Assessment: Don't Get Lost in an Echo Chamber!
30. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
31. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results
32. A Combination Of Left Atrial To Left Ventricular Volume Ratio And Body Mass Index Effectively Discriminates Heart Failure With Preserved Ejection Fraction
33. Current Trends In TTR Cardiac Amyloidosis Diagnosis And Public Interest
34. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results
35. The Transition From Chronic Intravenous To Oral Levosimendan Is Safe And Effective In Patients With Pulmonary Hypertension With Heart Failure And Preserved Ejection Fraction
36. Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial
37. Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure
38. Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity
39. Tafamidis Reduces The Decline In Longitudinal Strain And Stroke Volume In Patients With Transthyretin Amyloid Cardiomyopathy
40. Correlates Of Plasma Nt-probnp To Cyclic Gmp Ratio In Heart Failure With Preserved Ejection Fraction: An Analysis Of The Relax Trial
41. Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial
42. Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure
43. Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT
44. Association of the Fourth Heart Sound With Increased Left Ventricular End-Diastolic Stiffness
45. Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study
46. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
47. Endovascular Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction - First-in-human Clinical Trial
48. Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial
49. High-Sensitivity C-Reactive Protein and Parameters of Left Ventricular Dysfunction
50. Coronary Microvascular Dysfunction and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.